Georgios Batzias

Application and validation of a LC/fluorescence method for the determination of amoxicillin in sheep serum and tissue cage fluid.

A LC method with fluorescence detection after pre-column mercury dichloride derivation was developed and validated for the quantitative determination of amoxicillin in sheep blood serum and tissue cage fluid at levels down to 100 and 200ng/mL, respectively. Spiked blood serum and tissue cage fluid samples were deproteinized, derivatized with mercury dichloride and extracted prior to reversed phase LC analysis with fluorescence spectrophotometric detection at an excitation wavelength of 355nm and an emission wavelength of 435nm. Separation was carried out on a C(18) column with a mobile phase consisting of phosphate buffer, octanesulphonate sodium (OCT), and acetronitrile. A regression model using 1/concentration weighting was found the most appropriate for quantification. The intra-day precision for serum was 1.65-8.74% and for tissue cage fluid was 2.48-6.27%. The inter-day precision for serum was 0.39-3.57% and for tissue cage fluid was 0.44-2.54%. The overall precision over 3 days for blood serum using of 108 replicates was 1.70-9.44% and for tissue cage fluid using of 54 replicates was 2.51-6.76%. Studies of amoxicillin stability in blood serum and tissue cage fluid indicated that amoxicillin was stable after 4 weeks storage at -85 degrees C. The method was successfully applied for the determination of amoxicillin in blood serum and tissue cage fluid samples collected from rams after intravenous administration.

New simple liquid chromatographic method for the determination of trimethoprim, sulfadiazine and N4-acetylsulfadiazine in plasma of broilers

A new method for simultaneous quantification of trimethoprim, sulfadiazine and N4-acetylsulfadiazine in plasma of broilers at levels down to 13-16 ng/ml has been developed. Samples were deproteinized with acetonitrile, defatted with hexane, and extracted with dichloromethane. Chromatographic analysis was carried out on a C18 column in the presence of tetrabutylammonium hydrogen sulfate, a competing base, while detection was performed at 240 nm for trimethoprim, and 270 nm for both sulfadiazine and N4-acetylsulfadiazine. Accuracy and precision data showed recoveries and relative standard deviation values better than 87.3% and 3.1%, respectively, for all three analytes. The good analytical characteristics of the method could allow limits of detection in the low ng/ml range to be realised. The method was successfully applied to determine drug concentrations in plasma samples from broilers administered a combination of sulfadiazine and trimethoprim.

Bioavailability and pharmacokinetics of sulphadiazine, N4-acetylsulphadiazine and trimethoprim following intravenous and intramuscular administration of a sulphadiazine/trimethoprim combination in sheep.

The combination of sulphadiazine and trimethoprim is extensively used in farm animal species; however, there are no data concerning its pharmacokinetics after intramuscular administration in sheep. Twelve rams of the Chios breed were used to study the disposition of sulphadiazine, its metabolite N4-acetylsulphadiazine and trimethoprim after intravenous (i.v.) and intramuscular (i.m.) administration of a sulphadiazine/trimethoprim (5:1) combination in sheep. Sulphadiazine bioavailability (±SD) was 69.00%±10.51%. The half-life of the terminal phase (4.10±0.58 h afteri. v., and 4.03±0.31 h after i.m. administration) was significantly higher than the respective value for trimethoprim (0.59±0.19 h) afteri.v. administration. The maintenance of a constant plasma concentration ratio after i.v. administration was therefore impossible. The acetylation capacity in sheep, determined by the AUC ratio between N4-acetylsulphadiazine and the parent compound, sulphadiazine, was very low (less than 4%). The most remarkable finding of this study was that trimethoprim was not detected in sheep plasma after i.m. injection. In conclusion, according to the findings of the present study, following i.v. administration of the sulphadiazine/trimethoprim combination, trimethoprim can be considered as the limiting factor for any possible synergistic effect, and the i.m. route cannot be recommended in sheep.

Sorption of the antiparasitic drug eprinomectin in three soils.

Batch equilibrium studies were conducted to determine eprinomectin partitioning behavior in three Greek soils (agricultural, pastoral and riparian soil). An analytical method was developed to quantify eprinomectin in aqueous 0.01 M CaCl₂. Recovery was 95% and limits of detection and quantification were both 0.005 mgL⁻¹. An existing method for its quantification in soil was successfully tested in this study. Mass balance determinations showed that we accounted for 89-98% of the eprinomectin spiked in 5 g soil/25 mL 0.01 M CaCl₂. The concentration specific adsorption distribution coefficient (K(d)(ads)) ranged from 6.4 to 21.4 L kg⁻¹ while concentration specific desorption distribution coefficient (K(d)(des)) ranged from 23.2 to 124.6 L kg⁻¹. The Freundlich model adequately described adsorption and desorption with n values from 0.6 to 1.07. Hysteresis between adsorption and desorption was observed in two (agricultural and pastoral) soils. Moreover, eprinomectin binding to the clay mineral vermiculite and natural peat was tested. The drug binds to both materials. Hydroxyl groups and the nitrogen group present in eprinomectin are probably responsible for the binding to vermiculite. Coefficient K(d)(ads) significantly correlated with cation exchange capacity (CEC), Fe and Cu content of the soils when data for eprinomectin and data for ivermectin and abamectin were combined. These could be evidence that eprinomectin fate is related not only to organic matter (lipophilic binding) but also to clay content and other charged inorganic groups typically present in the soil environment.

Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits.

Aim: The study investigates the potential interaction of the herbal medicinal product of Rhodiola rosea on the pharmacokinetics of losartan and its active metabolite EXP3174 after concurrent oral administration to rabbits. Materials and Methods: We conducted a randomized, single-dose, two-treatment, two-period, two-sequence, cross-over pharmacokinetic study on 6 healthy female New Zealand rabbits, after concurrent oral administration of losartan (5 mg/kg) and the herbal medicinal product of R. rosea (50 mg/kg). Quantification of losartan and its main active metabolite EXP3174 was achieved using a validated HPCL/UV method. Pharmacokinetic and statistical analysis was performed using the EquivTest/PK software. Observations: Administration of the herbal medicinal product of R. rosea resulted in a statistically significant increase of the following pharmacokinetic parameters for losartan: the maximum plasma concentration (Cmax), the area under the curve (AUC) and the apparent total body clearance (CL/F). An almost 2-fold increase in the AUC of losartan was observed after concurrent administration of the herbal medicinal product of R. rosea. No statistically significant alteration was observed in the pharmacokinetic parameters of the active metabolite of losartan EXP3174. Conclusion: The data of this study suggest that R. rosea significantly alters the pharmacokinetic properties of losartan after concurrent oral administration to rabbits. A study in humans should be conducted to assess the clinical significance of a possible herb-drug interaction between the herbal medicinal products of R. rosea and drugs such as losartan, which are substrates of both CYPs and P-gp.

Analytical procedure for the determination of eprinomectin in soil and cattle faeces.

A new analytical HPLC-fluorescence method was developed for the quantitative determination of eprinomectin (EPM) in soil and cattle faeces. EPM was extracted with acetone and acetonitrile from soil and cattle faeces, respectively. Solid phase extraction and derivatization reaction with N-methylimidazole in the presence of trifluoroacetic anhydride and acetic acid were applied. The limit of quantitation was 1 ng g(-1) air dried soil and 2.5 ng g(-1) moist cattle faeces. Overall recovery (RSD) was 89% (8) in soil and 85% (10) in cattle faeces and its good reproducibility (RSD<15%) allows the application of the method in advanced ecotoxicological studies, required for the environmental fate assessment of EPM.

Influence of the injection site on the pharmacokinetics of amoxicillin after intramuscular administration of a conventional and a long-acting formulation in sheep.

The pharmacokinetics of amoxicillin (AMX) were investigated in sheep following intravenous (i.v.) and intramuscular (i.m) injection, comparing two different drug formulations, a conventional and a long-acting AMX-trihydrate suspension. For the i.m. application two different injections sites, the neck area and the hind limb were used to identify possible differences in the kinetic parameters related to the site of injection. A three-compartment open model could best describe AMX disposition after i.v. administration. Data analysis after i.m. administration of the conventional suspension at both injection sites revealed the occurrence of a flip-flop phenomenon, clearly indicating that absorption of AMX is the rate-limiting step of its overall disposition. A moderate effect of the injection site was observed with a tendency for the neck area to be advantageous, mainly in terms of rate rather than extent of absorption. Injection of the long-acting formulation led to a focal depot formation, thus yielding lower but remarkably prolonged serum AMX levels reflected in the respective terminal half-lives. The concentration-time profile of AMX after administration of the long-acting formulation was less affected by the injection site, but the low serum levels justify its use only in cases in which a high susceptibility of the involved bacterial population is confirmed.

Emergence and maintenance of multidrug-resistant Escherichia coli of canine origin harbouring a blaCMY-2-IncI1/ST65 plasmid and topoisomerase mutations

OBJECTIVES To characterize the mechanisms implicated in fluoroquinolone (FQ) and expanded-spectrum cephalosporin (ESC) resistance in three clinical and seven faecal multidrug-resistant (MDR; resistant to at least three antimicrobial classes) Escherichia coli isolates from a dog with atopic dermatitis, also suffering from recurrent otitis, that had already been exposed to prolonged antimicrobial treatment and colonized for a long period. METHODS MICs of FQs, ESCs and other antimicrobials were determined by the broth microdilution method. Phenotypic tests (efflux pump inhibition and combination disc tests) and isoelectric focusing were combined with genotypic analyses [PCRs, sequencing, conjugation, S1 nuclease PFGE, PCR-based replicon typing, plasmid multilocus sequence typing (pMLST) and PCR mapping] to characterize the molecular basis of FQ and ESC resistance. Isolates were further characterized by MLST and PFGE. RESULTS Three otitis and five faecal isolates with enrofloxacin MICs of 32 to >128 mg/L displayed the GyrA:S83L+D87N/ParC:E62K/ParE:G545D pattern harbouring novel ParC and ParE substitutions, whereas the two remaining faecal isolates were susceptible or borderline resistant single-step mutants (GyrA:S83L pattern) and carried qnrS1. Efflux pump overexpression also contributed to FQ resistance and the MDR phenotype. The three otitis and five faecal isolates also exhibited cefoxitin/ceftazidime MICs of 32-64 mg/L and harboured blaCMY-2, adjusted to ISEcp1, on an IncI1/ST65 conjugative plasmid, previously described in Salmonella Heidelberg from poultry. Interestingly, all isolates shared an identical MLST type (ST212), with the otitis isolates showing indistinguishable patterns with the high-level resistant faecal E. coli isolates. CONCLUSIONS The long-term maintenance of FQ- and ESC-resistant clones harbouring topoisomerase mutations and a blaCMY-2-IncI1/ST65 plasmid in canine commensal flora after prolonged antimicrobial use may contribute to the dissemination of multidrug resistance.

Are the parasiticidal avermectins resistant to dissipation in the environment? The case of eprinomectin

Eprinomectin (EPM) is a veterinary drug currently licensed in many countries for the treatment of endo- and ecto-parasites in cattle. Despite the notable evidence for its high toxicity to the terrestrial and aquatic environment ecosystems, its environmental behavior and fate are currently unknown. In the present research, the dissipation of EPM was studied in three soils and in cattle manure by using the OECD 307 guideline and the recently developed European Medicines Agency (EMA/CVMP/ERA/430327) guideline, respectively. The procedure presented by the FOrum for Co-ordination of pesticide models and their USe (FOCUS) was adopted for estimating the EPM degradation kinetics in soil and cattle manure. The EPM dissipation in soil was best described by the SFO (Simple First Order) and the HS (Hockey Stick) models, under aerobic and anaerobic conditions, respectively. The EPM dissipation in cattle manure was best described by the FOMC (First Order Multi Compartment) model. The Dissipation Time for the 50% of the initial EPM mass (DT50) range was 38-53days under aerobic and 691-1491days under anaerobic conditions. In addition, the DT50 for EPM in cattle manure was 333days. Therefore, EPM could be characterized as moderately to highly persistent to dissipation in soil, which depends on soil type, its oxygen content (aerobic or anaerobic conditions in soil) and the microbial activity. Moreover, the EPM resists dissipation in cattle manure, resulting to a high load in soil after manure application in agricultural land (or direct defecation in grassland). Consequently, the high possibility for EPM accumulation in soil and cattle manure should be considered when assessing the environmental risk of the drug.

Peripheral distribution of amoxicillin in sheep and influence of local inflammation.

The pharmacokinetics of amoxicillin (AMX) in blood serum (SBS) and tissue cage fluid (TCF) was studied in sheep. Four tissue cages, prepared from silicone rubber tubing, were subcutaneously inserted in the neck area (two on each side) of the experimental animals and AMX was administered both intravenously (IV) and intramuscularly (IM) at the dose rate of 15mg/kg bodyweight. The impact of local inflammation on AMX distribution in TCF was studied after intra-cavity injection of a lambda carrageenan solution in one of the two tissue cages used after each administration. In contrast to the three-compartment AMX disposition after IV injection, two-compartment, absorption-limited pharmacokinetics was observed after IM administration. Non-inflamed and inflamed TCF data revealed, in all cases, the attainment of low, but prolonged concentrations and absence of an inflammation-induced effect on AMX penetration into and elimination from TCF.